Atezolizumab (anti-PD-L1)

目录号：A2004         批次号: A200409

打印

Atezolizumab (anti-PD-L1)是人源、IgG1单克隆抗体，阻止PD-L1与PD-1和B7.1的相互作用，但不影响PD-L2与PD-1的相互作用；MW：145 KD。

抗体信息

CAS号 1380723-44-3
配制 PBS buffer, pH 7.2
推荐同型对照 Human IgG1
来源 CHO cells
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
纯度 99%
蛋白浓度 7.2mg/ml
内毒素 ＜1EU/mg

客户使用selleck产品的实验数据

Atezolizumab (anti-PD-L1)在文献中得到引用

[ Int Immunopharmacol, 2024, ] PubMed: 38442580
Pivotal role of myeloid-derived suppressor cells in infection-related tumor growth [ Cancer Med, 2024, 13(4):e6917] PubMed: 38457241
Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN [ Research Square, 2024, 10.21203/rs.3.rs-3782509/v1] PubMed: none
Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy [ J Extracell Vesicles, 2023, 12(11):e12379] PubMed: 37974395
YAP1 expression is associated with survival and immunosuppression in small cell lung cancer [ Cell Death Dis, 2023, 14(9):636] PubMed: 37752152
YAP1 expression is associated with survival and immunosuppression in small cell lung cancer [ Cell Death Dis, 2023, 14(9):636] PubMed: 37752152
Synergistically Enhancing Immunotherapy Efficacy in Glioblastoma with Gold-Core Silica-Shell Nanoparticles and Radiation [ Int J Nanomedicine, 2023, 18:7677-7693] PubMed: 38111846
Analysis of the mechanisms regulating soluble PD-1 production and function in human NK cells [ Front Immunol, 2023, 14:1229341] PubMed: 37638041
ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma [ J Transl Med, 2023, 21(1):341] PubMed: 37217923
Self-assembled albumin nanoparticles induce pyroptosis for photodynamic/photothermal/immuno synergistic therapies in triple-negative breast cancer [ Front Immunol, 2023, 14:1173487] PubMed: 37342347

禁止用于人体及治疗！